Core Viewpoint - 华检医疗's stock has surged over 200% in the past four weeks, reflecting strong market interest and investor confidence following a strategic partnership announcement [1] Group 1: Stock Performance - 华检医疗's stock price increased by 9% during trading, reaching 6.17 HKD, with a trading volume of 23.32 million HKD [1] - The cumulative increase over the last four weeks has exceeded 200% [1] Group 2: Strategic Partnership - On July 30, 华检医疗 announced a strategic cooperation framework agreement with 华大共赢 to establish the "华检华大共赢创新药知识产权代币化基金" [1] - The fund will invest in 华检医疗's "NewCo+RWA" Web3 exchange ecosystem projects in Hong Kong, the United States, and other locations [1] Group 3: Industry Innovation - The "IVDNewCo Exchange" aims to address significant pain points in the pharmaceutical industry, where new drug development takes about 10 years, with 80% of funding spent in clinical stages [1] - 华检医疗's solution involves converting high-value medical assets, such as phase II clinical ADC drugs and gene therapy patents, into tradable digital tokens using RWA technology [1] - The goal is to become a "Nasdaq + Uniswap" in the medical RWA field, ensuring compliance while achieving decentralized liquidity [1]

Core Viewpoint - Huajian Medical (01931) has seen a significant stock price increase, with a cumulative rise of over 200% in the past four weeks, indicating strong market interest and potential investor confidence in the company's strategic initiatives [1] Group 1: Strategic Developments - On July 30, Huajian Medical announced a strategic cooperation framework agreement with BGI Genomics to establish the "Huajian BGI Win-Win Innovation Drug Intellectual Property Tokenization Fund" [1] - The fund will invest in Huajian Medical's "NewCo+RWA" Web3 exchange ecosystem projects in regions including Hong Kong and the United States [1] - BGI Win-Win, initiated by BGI Genomics, is a corporate venture capital entity with extensive experience and resources in the innovative medical and drug sectors [1] Group 2: Market Positioning - The company is developing a Web3 exchange ecosystem named "IVDNewCo Exchange" aimed at addressing critical pain points in the pharmaceutical industry, particularly the lengthy and costly drug development process [1] - The solution involves converting high-value medical assets, such as phase II clinical ADC drugs and gene therapy patents, into tradable digital certificates using RWA technology [1] - The goal is to position itself as the "Nasdaq + Uniswap" of the medical RWA sector, ensuring compliance while achieving decentralized liquidity [1]

截至月份: 2025年7月31日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01931 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 3,000,000,000 | USD | | 0.0005 | USD | | 1,500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 3,000,000,000 | USD | | 0.0005 | USD | | 1,500,000 | 本月底法定/註冊股本總額： USD 1,500,000 FF301 致：香港交易及結算所有限公司 公司名稱: 華 ...

Core Insights - The emergence of RWA (Real World Assets) is revolutionizing the innovative pharmaceutical industry, shifting from "license-out" to "asset optionization" for global expansion [1] - Two companies, Huajian Medical and Hanyu Pharmaceutical, have recently launched RWA projects that unlock liquidity in the pharmaceutical sector, indicating a paradigm shift in how Chinese innovative drugs can access global markets [1] Group 1: RWA and Market Dynamics - RWA utilizes blockchain technology to tokenize real-world assets, enabling on-chain transactions and enhancing liquidity in traditionally illiquid markets [2] - The RWA market is projected to reach $4.5 trillion by 2030, with significant contributions from the pharmaceutical sector, which is expected to see rapid growth in asset tokenization [4] - The current tokenization of only 0.1% of medical assets presents a vast growth opportunity, with the potential for the medical asset share in the RWA market to exceed 20% by 2030 [11] Group 2: RWA vs Traditional Finance - RWA offers higher liquidity compared to traditional finance, allowing for real-time global trading of tokens, while traditional financing methods often involve lengthy cycles [5] - The entry barrier for investors is significantly lowered in RWA, allowing retail investors to participate with minimum investments, contrasting with the high capital requirements of traditional financing [5] - RWA provides greater transparency through immutable on-chain records, unlike traditional finance which relies on audit reports [5] Group 3: Challenges and Solutions - Traditional licensing models face issues such as valuation discounts and long cycles, which RWA aims to address by allowing for the tokenization of future revenue streams [6][7] - RWA can diversify risk by enabling retail investors to share in the funding of drug development, thus reducing the financial burden on single institutions [7] - The recent regulatory developments, such as the implementation of the "Stablecoin Regulation" in Hong Kong, create a conducive environment for RWA projects in the pharmaceutical sector [10] Group 4: Future Outlook - The successful implementation of RWA could release trillions in dormant assets from over 3,000 clinical pipelines in China, transforming the global positioning of Chinese pharmaceutical companies [23] - The collaboration between pharmaceutical companies and blockchain platforms is expected to redefine the relationship between capital, research, and market dynamics, moving towards a new era of global pricing power for Chinese drugs [23]

Market Overview - Hong Kong stocks opened lower but closed higher, with all three major indices ending in the green. The Hang Seng Index rose by 0.92% or 225.64 points, closing at 24,733.45 points, with a total turnover of HKD 2,346.82 million [1] - The Hang Seng Tech Index performed well, increasing by 1.55% to 5,481.25 points, indicating a healthy overall upward trend in the market driven by improving fundamentals and positive policy expectations [1] Blue Chip Performance - New Oriental Education (02057) led blue-chip stocks, rising by 6.49% to HKD 36.58, contributing 2.7 points to the Hang Seng Index. The company reported a 9.4% year-on-year revenue growth for the fourth fiscal quarter, exceeding market expectations [2] - Other notable blue-chip performances included Zhongsheng Holdings (00881) up 5.59%, Lenovo Group (00992) up 4.95%, while Xinyi Glass (00868) fell by 5.87% [2] Sector Highlights - Gold stocks surged due to lower-than-expected U.S. non-farm payroll data, with Shandong Gold (01787) rising by 10.7% and Chifeng Jilong Gold (06693) up 8.89% [3] - Semiconductor stocks also saw significant gains, with Hua Hong Semiconductor (01347) increasing by 8.69% and Shanghai Fudan (01385) up 5.66%, driven by ongoing AI demand and domestic substitution expectations [4] Stablecoin Sector - Stablecoin concept stocks continued to decline, with Yunfeng Financial (00376) down 6.91% and Guotai Junan International (01788) down 6.48%. The recent implementation of the Stablecoin Regulation in Hong Kong has led to stricter licensing requirements, delaying the issuance of licenses until early 2026 [5][6] Notable Stock Movements - InnoCare (02577) saw a significant increase of 30.47% after announcing a partnership with NVIDIA to promote a new power architecture for AI data centers [7] - Huajian Medical (01931) rose by 20.7% following a strategic cooperation agreement with BGI to establish a fund for innovative drug tokenization [8] - Conversely, China Resources Medical (01515) fell by 15.58% due to a profit warning indicating a potential 20% to 25% decline in profit for the upcoming six months [9] Earnings Reports - Xinjiang Xinmin Mining (03833) issued a profit warning, expecting a 50.8% decline in net profit compared to the previous year, despite a slight increase in revenue [10]

Market Overview - Hong Kong stocks opened lower but closed higher, with all three major indices ending in the green. The Hang Seng Index rose by 0.92% to 24,733.45 points, with a total turnover of HKD 234.68 billion [1] - The overall upward trend in Hong Kong stocks is considered healthy, shifting from previous risk-averse sentiment to improvements in fundamentals and positive policy expectations [1] Blue Chip Performance - New Oriental-S (02057) led blue-chip stocks, rising by 6.49% to HKD 36.58, contributing 2.7 points to the Hang Seng Index. Its revenue for the fourth fiscal quarter grew by 9.4% year-on-year, exceeding market expectations [2] - Other notable blue-chip performances included Zhongsheng Holdings (00881) up 5.59%, Lenovo Group (00992) up 4.95%, while Xinyi Glass (00868) fell by 5.87% [2] Sector Highlights - Gold stocks performed strongly due to lower-than-expected U.S. non-farm payroll data, with Shandong Gold (01787) rising by 10.7% and Chifeng Jilong Gold Mining (06693) up 8.89% [3] - Semiconductor stocks also saw significant gains, with Hua Hong Semiconductor (01347) up 8.69% and Shanghai Fudan (01385) up 5.66% [4] Stablecoin Sector - The stablecoin sector continued to decline, with Yunfeng Financial (00376) down 6.91% and Guotai Junan International (01788) down 6.48%. The Hong Kong Monetary Authority's new regulations on stablecoins are expected to delay the issuance of licenses until early 2026 [5][6] Notable Stock Movements - InnoCare Pharma (02577) surged by 30.47% after announcing a partnership with NVIDIA to promote a new power architecture for AI data centers [7] - Huajian Medical (01931) rose by 20.7% following a strategic cooperation agreement with BGI [8] - China Resources Medical (01515) fell by 15.58% due to a profit warning, expecting a decline of 20% to 25% in profit for the upcoming six months [9]

华检医疗控股有限公司于2016年01月15日根据开曼群岛法注册成立,其主要业务为投资控股。集团在中 国香港设有三家子公司,威士达医疗有限公司、中华检验国际有限公司及艾维德(中国)有限公司。三家子 公司在中国大陆各设有子公司或分公司,在全国各主要城市设有办事处。公司拥有超700名员工,主要从事 研发、生产、销售体外诊断的医疗仪器及耗材,业务遍布中国及中国香港。从1993年创立威士达医疗有 限公司,公司专注体外诊断业务,经过二十多年的发展,公司现已成为中国领先的体外诊断业务的专业公司, 为中国检验界提供超值产品及服务。 （以上内容为金融界基于公开消息，由程序或算法智能生成，不作为投资建议或交易依据。） 来源：金融界 截至8月4日收盘，华检医疗（01931.HK）报5.480港元，较上个交易日上涨20.7%，当日盘中最高价触 及5.500港元，创近一年新高。 资金流向方面，当日主力流入NaN万港元，流出NaN万港元，净流入805.45万港元。 ...

Core Viewpoint - 华检医疗's stock price has surged nearly 13% in the afternoon, with a cumulative increase of over 130% in the past two weeks, reflecting strong market interest and strategic developments [1] Group 1: Strategic Developments - 华检医疗 has announced a strategic cooperation framework agreement with 华大共赢 to establish the 华检华大共赢创新药知识产权代币化基金 (IVD-BGI CoWin), which will invest in projects under the NewCo + RWA Web3 exchange ecosystem in Hong Kong, the US, or other overseas regions [1] - The fund is initiated by 华大基因, a leader in biotechnology, which brings years of investment experience and project resources in the innovative medical and pharmaceutical sectors [1] Group 2: Market Performance - Following the announcement of a dual primary listing in the US on July 14 and the launch of a new brand logo on July 30, 华检医疗's market capitalization has increased from 3.6 billion to nearly 8 billion HKD [1] - The company has positioned itself as a "new species" in the capital market through a combination of "stablecoins + medical RWA," indicating a significant shift in traditional medical finance [1] Group 3: Future Prospects - Applications for stablecoin licenses in New York and Hong Kong are ongoing, and the listing on Nasdaq has yet to occur, suggesting potential future growth and opportunities for 华检医疗 [1] - The strategic actions taken in July are likened to a surgical strike, utilizing Web3 technology to transform innovative pharmaceutical assets into "digital gold" on the blockchain [1]

Group 1 - The core point of the article is that Huajian Medical (1931.HK) has seen a significant stock price increase, rising 18.28% to reach a historical high of 5.36 HKD, with a total market capitalization of 8.698 billion HKD [1] - Since July 15, the stock has accumulated a rise of over 165% [1] - The company announced a strategic cooperation framework agreement with BGI CoWin (Shenzhen) Equity Investment Fund Management Co., Ltd., to jointly establish the Huajian BGI CoWin Innovation Drug Intellectual Property Tokenization Fund (IVD-BGI CoWin) [1] Group 2 - The fund will invest in projects under the company's NewCo+RWA Web3 exchange ecosystem operation model [1]

Core Viewpoint - 华检医疗 (1931.HK) has experienced a significant stock price increase, rising 18.28% to reach a historical high of 5.36 HKD, with a total market capitalization of 8.698 billion HKD. Since July 15, the stock has accumulated a gain of over 165% [1] Group 1 - The company has entered into a strategic cooperation framework agreement with 华大共赢 (Shenzhen) Equity Investment Fund Management Co., Ltd. [1] - The partnership aims to establish the 华检华大共赢 Innovation Drug Intellectual Property Tokenization Fund (IVD-BGI CoWin) [1] - The fund will invest in projects under the company's NewCo+RWA Web3 exchange ecosystem operation model [1]